Probiodrug completes financing round for Alzheimer's drug
Probiodrug, a privately held biotech firm in Germany, raised $53 million in its second financing round for an Alzheimer's disease drug program. The company plans to use the funds to conduct further trials of a treatment that blocks glutaminyl cyclase, a brain enzyme that appears to contribute to plaque buildup linked to Alzheimer's.
Reuters | 11/02
This story published in BIO SmartBrief on 11/03/2009
More from SmartBrief:
Protein could be therapeutic target for Alzheimer's, diabetes
Thursday, July 23, 2009
Targacept, AstraZeneca expand drug-licensing deals
Thursday, July 9, 2009
Study links clusters of amyloid protein to memory impairment
Thursday, July 30, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|